Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ZoetisBayer AktiengesellschaftVertex PharmaceuticalsTakeda PharmaceuticalGlaxoSmithKline
SymbolNYSE:ZTSOTCMKTS:BAYRYNASDAQ:VRTXNYSE:TAKNYSE:GSK
Price Information
Current Price$167.63$16.22$219.39$17.08$37.75
52 Week RangeBuyHoldBuyHoldHold
MarketRank™
Overall Score2.21.02.21.31.1
Analysis Score1.30.04.40.00.0
Community Score3.22.33.22.12.0
Dividend Score1.72.50.03.31.7
Ownership Score3.30.01.70.00.0
Earnings & Valuation Score1.30.01.91.31.9
Analyst Ratings
Consensus RecommendationBuyHoldBuyHoldHold
Consensus Price Target$170.08N/A$293.13N/AN/A
% Upside from Price Target1.46% upsideN/A33.61% upsideN/AN/A
Trade Information
Market Cap$79.62 billion$60.50 billion$56.78 billion$53.90 billion$101.65 billion
Beta0.711.340.791.010.67
Average Volume2,077,499460,7772,044,8313,885,7196,090,994
Sales & Book Value
Annual Revenue$6.26 billion$48.23 billion$4.16 billion$30.20 billion$43.10 billion
Price / Sales12.721.2513.641.782.36
Cashflow$4.77 per share$3.56 per share$4.74 per share$3.27 per share$4.34 per share
Price / Cash35.174.5546.275.238.69
Book Value$5.69 per share$14.27 per share$23.66 per share$13.80 per share$9.40 per share
Price / Book29.461.149.271.244.02
Profitability
Net Income$1.50 billion$4.58 billion$1.18 billion$407.02 million$5.93 billion
EPS$3.64$1.77$4.29$1.78$3.17
Trailing P/E Ratio49.74N/A27.7056.9411.62
Forward P/E Ratio40.698.4523.627.8012.26
P/E Growth4.356.101.25N/A2.93
Net Margins25.50%-22.32%38.51%3.04%18.50%
Return on Equity (ROE)63.89%14.23%28.55%13.46%29.60%
Return on Assets (ROA)14.99%5.01%20.68%5.02%7.11%
Dividend
Annual Payout$1.00$0.53N/A$0.72$2.52
Dividend Yield0.60%3.27%N/A4.22%6.68%
Three-Year Dividend GrowthN/AN/AN/A6.41%-1.26%
Payout Ratio27.47%29.94%N/A40.45%79.50%
Years of Consecutive Dividend Growth1 YearsN/AN/AN/A1 Years
Debt
Debt-to-Equity Ratio2.41%1.12%0.07%0.99%1.13%
Current Ratio3.47%1.10%3.72%1.51%0.90%
Quick Ratio2.60%0.81%3.60%1.08%0.61%
Ownership Information
Institutional Ownership Percentage92.50%N/A92.17%3.41%11.83%
Insider Ownership Percentage0.17%N/A0.70%N/A10.00%
Miscellaneous
Employees11,30095,9553,40047,49599,437
Shares Outstanding474.99 million3.73 billion258.82 million3.16 billion2.69 billion
Next Earnings Date5/6/2021 (Confirmed)4/26/2021 (Estimated)5/5/2021 (Estimated)5/12/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableOptionable
SourceHeadline
GlaxoSmithKline shares jump at news of activist hedge fund interest - The GuardianGlaxoSmithKline shares jump at news of activist hedge fund interest - The Guardian
theguardian.com - April 15 at 6:47 PM
GlaxoSmithKline Target of Unusually Large Options Trading (NYSE:GSK)GlaxoSmithKline Target of Unusually Large Options Trading (NYSE:GSK)
americanbankingnews.com - April 15 at 5:36 PM
Zacks: Brokerages Anticipate GlaxoSmithKline plc (NYSE:GSK) to Post $0.69 EPSZacks: Brokerages Anticipate GlaxoSmithKline plc (NYSE:GSK) to Post $0.69 EPS
americanbankingnews.com - April 15 at 4:46 PM
GSK vaccine R&D chief jumps ship to Viome amid COVID-19 vaccine setbacks - FierceBiotechGSK vaccine R&D chief jumps ship to Viome amid COVID-19 vaccine setbacks - FierceBiotech
fiercebiotech.com - April 15 at 1:47 PM
FTSE 100 ends higher on GlaxoSmithKline boost; midcaps at record highs - Reuters UKFTSE 100 ends higher on GlaxoSmithKline boost; midcaps at record highs - Reuters UK
reuters.com - April 15 at 1:47 PM
GlaxoSmithKline (NYSE:GSK) Sees Strong Trading VolumeGlaxoSmithKline (NYSE:GSK) Sees Strong Trading Volume
americanbankingnews.com - April 15 at 11:40 AM
GlaxoSmithKlines head of vaccine R&D is jumping to a wellness company concentrating on the microbiome as reports of an exodus start to spread - Endpoints NewsGlaxoSmithKline's head of vaccine R&D is jumping to a wellness company concentrating on the microbiome as reports of an exodus start to spread - Endpoints News
endpts.com - April 15 at 8:47 AM
GlaxoSmithKline Inc. (GSK) stock rises in the pre-market trading. Lets find out why? - Catching NewsGlaxoSmithKline Inc. (GSK) stock rises in the pre-market trading. Let's find out why? - Catching News
catchingnews.com - April 15 at 8:47 AM
GlaxoSmithKline shares surge on report Elliott Management building a stake - MarketWatchGlaxoSmithKline shares surge on report Elliott Management building a stake - MarketWatch
marketwatch.com - April 15 at 8:47 AM
GlaxoSmithKline and Merck discontinue trials... - MorningstarGlaxoSmithKline and Merck discontinue trials... - Morningstar
morningstar.co.uk - April 15 at 8:47 AM
Activist investor Elliott takes multibillion pound stake in GSK, FT saysActivist investor Elliott takes multibillion pound stake in GSK, FT says
ca.finance.yahoo.com - April 15 at 8:47 AM
Elliott Is Said to Build Significant Stake in Drugmaker GSKElliott Is Said to Build Significant Stake in Drugmaker GSK
finance.yahoo.com - April 15 at 8:47 AM
GlaxoSmithKline shares surge on report Elliott Management building a stakeGlaxoSmithKline shares surge on report Elliott Management building a stake
finance.yahoo.com - April 15 at 8:47 AM
EMA starts review of GSKs monoclonal antibody to treat COVID-19 patientsEMA starts review of GSK's monoclonal antibody to treat COVID-19 patients
finance.yahoo.com - April 15 at 8:47 AM
GlaxoSmithKline : GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist - Marketscreener.comGlaxoSmithKline : GSK provides update on feladilimab, an investigational inducible T cell co-stimulatory (ICOS) agonist - Marketscreener.com
marketscreener.com - April 15 at 1:17 AM
GlaxoSmithKline scraps two key mid-stage trials for their ICOS drug in the latest setback for the field - Endpoints NewsGlaxoSmithKline scraps two key mid-stage trials for their ICOS drug in the latest setback for the field - Endpoints News
endpts.com - April 14 at 8:17 PM
GlaxoSmithKline is facing an uncertain vaccine future - Business InsiderGlaxoSmithKline is facing an uncertain vaccine future - Business Insider
businessinsider.com - April 13 at 2:03 PM
Zentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline - marketscreener.comZentalis Pharmaceuticals in Collaboration Agreement With GlaxoSmithKline - marketscreener.com
marketscreener.com - April 13 at 2:41 AM
Zentalis Pharmaceuticals (ZNTL) Stock Rises On Collaboration Pact with GlaxoSmithKline - InvestorsObserverZentalis Pharmaceuticals (ZNTL) Stock Rises On Collaboration Pact with GlaxoSmithKline - InvestorsObserver
investorsobserver.com - April 13 at 2:41 AM
Zentalis surges on clinical collaboration with GlaxoSmithKline - Seeking AlphaZentalis surges on clinical collaboration with GlaxoSmithKline - Seeking Alpha
seekingalpha.com - April 13 at 2:41 AM
Questor: we’ve made an 11pc loss on GlaxoSmithKline. Here’s why we’re sticking with it - Telegraph.co.ukQuestor: we’ve made an 11pc loss on GlaxoSmithKline. Here’s why we’re sticking with it - Telegraph.co.uk
telegraph.co.uk - April 13 at 2:41 AM
Questor: we’ve made an 11pc loss on GlaxoSmithKline. Here’s why we’re sticking with itQuestor: we’ve made an 11pc loss on GlaxoSmithKline. Here’s why we’re sticking with it
uk.finance.yahoo.com - April 13 at 2:41 AM
Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline? - NasdaqWhich Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline? - Nasdaq
nasdaq.com - April 12 at 9:35 PM
Zentaliss Early WEE1 Inhibitor Data Shows Exceptional Response In Solid Tumor Study, Plans Combination TrialsZentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials
finance.yahoo.com - April 12 at 4:34 PM
GlaxoSmithKline - Im Not Buying It (Yet) - Seeking AlphaGlaxoSmithKline - I'm Not Buying It (Yet) - Seeking Alpha
seekingalpha.com - April 12 at 11:33 AM
GlaxoSmithKline (NYSE:GSK) Earns Market Perform Rating from SVB LeerinkGlaxoSmithKline (NYSE:GSK) Earns Market Perform Rating from SVB Leerink
marketbeat.com - March 29 at 9:06 AM
DateCompanyBrokerageAction
3/15/2021ZoetisBank of AmericaUpgrade
3/15/2021ZoetisRaymond JamesUpgrade
2/17/2021ZoetisCredit Suisse GroupBoost Price Target
11/13/2020ZoetisMorgan StanleyBoost Price Target
11/12/2020ZoetisTruistBoost Price Target
11/6/2020ZoetisBarclaysBoost Price Target
9/21/2020ZoetisAtlantic SecuritiesInitiated Coverage
8/14/2020ZoetisEdward JonesUpgrade
8/12/2020ZoetisG.ResearchDowngrade
8/12/2020ZoetisGabelliDowngrade
8/10/2020ZoetisTruist FinancialBoost Price Target
8/10/2020ZoetisCitigroupBoost Price Target
8/7/2020ZoetisStifel NicolausBoost Price Target
6/3/2020ZoetisArgusReiterated Rating
5/27/2020ZoetisJefferies Financial GroupInitiated Coverage
5/8/2020ZoetisUBS GroupLower Price Target
3/30/2021Bayer AktiengesellschaftDZ BankReiterated Rating
3/19/2021Bayer AktiengesellschaftDeutsche Bank AktiengesellschaftReiterated Rating
3/11/2021Bayer AktiengesellschaftSociete GeneraleReiterated Rating
3/4/2021Bayer AktiengesellschaftBerenberg BankReiterated Rating
1/6/2021Bayer AktiengesellschaftNord/LBReiterated Rating
11/5/2020Bayer AktiengesellschaftJPMorgan Chase & Co.Reiterated Rating
10/2/2020Bayer AktiengesellschaftAlphaValueDowngrade
10/1/2020Bayer AktiengesellschaftBryan, Garnier & CoDowngrade
10/1/2020Bayer AktiengesellschaftHSBCDowngrade
4/11/2021Vertex PharmaceuticalsRoyal Bank of CanadaReiterated Rating
3/1/2021Vertex PharmaceuticalsRobert W. BairdUpgrade
2/2/2021Vertex PharmaceuticalsBMO Capital MarketsLower Price Target
2/2/2021Vertex PharmaceuticalsSVB LeerinkLower Price Target
2/2/2021Vertex PharmaceuticalsPiper SandlerBoost Price Target
2/2/2021Vertex PharmaceuticalsHC WainwrightLower Price Target
12/30/2020Vertex PharmaceuticalsDaiwa Capital MarketsInitiated Coverage
11/20/2020Vertex PharmaceuticalsSanford C. BernsteinInitiated Coverage
10/26/2020Vertex PharmaceuticalsNeedham & Company LLCReiterated Rating
9/18/2020Vertex PharmaceuticalsMaxim GroupReiterated Rating
11/1/2019Takeda PharmaceuticalCowenInitiated Coverage
3/19/2019Takeda PharmaceuticalThe Goldman Sachs GroupReiterated Rating
11/2/2020GlaxoSmithKlineLiberum CapitalUpgrade
9/23/2020GlaxoSmithKlineOddo BhfUpgrade
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.